Table 3.
Pharmacokinetic parameters and comparison between treatment groups
| Parameter | Test group | Reference group | Test/reference: LS mean ratio (95% CI) | |
|---|---|---|---|---|
| Rivaroxaban | AUC(0–24) | Warfarin/rivaroxaban (A) | Rivaroxaban alone (C) | 0.95 (0.82–1.10) |
| Cmax | Warfarin/rivaroxaban (A) | Rivaroxaban alone (C) | 0.99 (0.85–1.16) | |
| R-Warfarin | t1/2 | Warfarin/rivaroxaban (A) | Warfarin/placebo (B) | 1.00 (0.88–1.15) |
| S-Warfarin | t1/2 | Warfarin/rivaroxaban (A) | Warfarin/placebo (B) | 0.96 (0.86–1.07) |
Results are geometric means (n = 28). Abbreviations are as follows: AUC(0–24), area under the plasma concentration–time curve from time 0 to 24 h; CI, confidence interval; Cmax, maximal drug concentration in plasma; LS, least-squares; t1/2, terminal half-life.